NormOxys names first chief medical officer
This article was originally published in Scrip
NormOxys, a US biotechnology company developing small-molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, has appointed Dr David Clark as its first chief medical officer. He will manage the company's clinical affairs, including the development of its lead product candidate, OXY111A, which is expected to enter clinical trials in the first quarter of 2010. Dr Clark, who has more than 12 years' pharmaceutical drug development experience, previously led clinical teams while working in the clinical development division at Pfizer.